Genomic Profiling of Pancreatic Cystic Tumors
ConditionPancreatic Cyst
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19+
SponsorSamsung Medical Center
About this trial
This study aims to find out whether quantitative and qualitative analysis, including genetic mutation analysis, of samples obtained from patients with pancreatic cysts is associated with the risk of malignancy, and helpful in the differential diagnosis of mucinous and serous cysts. The study design is a single-arm prospective cohort observational study. Using blood, pancreatic cyst fluid, and pancreatic cyst tissue, genetic mutation analysis and measurement of various biomarkers are performed, and the relationship between these and malignancy or whether they are helpful in distinguishing mucinous and serous cysts is analyzed. The primary outcome is genetic variants of pancreatic cysts associated with malignancy. The secondary outcomes are factors including genetic variants that differentiate mucinous from serous cysts.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Pancreatic cyst patients undergoing cyst aspiration or biopsy or surgical resection
Patients who gave written informed consent
Disqualifiers
Anyone who has not signed a written consent form.
Patients deemed unsuitable for research (severe infection, drug abuse, severe mental illness, etc.)
Trial population
Pancreatic cyst patients undergoing cyst aspiration or biopsy or surgical resection
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
NA (No intervention)
Other interventionNA (No intervention)
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Genetic variants of pancreatic cysts associated with malignancy assessed by next-generation sequencing
Genetic variants showing significant differences between pancreatic cysts with high-grade dysplasia or invasive cancer and the remaining pancreatic cysts, assessed through next-generation sequencing
Time frame
Through study completion, an average of 3 yearsSecondary outcomes
1
Genetic variants that differentiate mucinous from serous cysts assessed by next-generation sequencing
Genetic variants indicating significant differences between mucinous and serous cysts, as evaluated through next-generation sequencing
Time frame
Through study completion, an average of 3 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: